|
|
Article: Preclinical Studies Underway on Advanced Refractive Technologies Novel Glaucoma Treatment.
- Article from:
- PR Newswire
- Article date:
- September 13, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN CLEMENTE, Calif., Sept. 13 /PRNewswire-FirstCall/ -- Preclinical testing has begun on the novel glaucoma treatment recently licensed by Advanced Refractive Technologies (BULLETIN BOARD: ARFR) . This first step in clinical trials will assess the safety and efficacy of the compound before the initiation of human trials. The in vitro portion of this testing will require approximately six months to complete at which time the in vivo testing will begin. After six months of this in vivo testing, the Phase One human trials should be underway.
This compound, derived from monoclonal antibodies, works specifically on one structure of the eye, known as Schlemm's ...